65,437 trials
2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer
Primary: Primary Cohort: Overall Survival (OS) Censored at 138 Deaths (ITT Set) — 3.8; 5.4; 4.6 months
Painful Bladder Syndrome
Primary: Change in O'Leary-Sant Interstitial Cystitis Symptom Index Score — -4.25; -6.2; 0; -1.8 units on a scale
Metastatic Melanoma
Primary: Progression-free Survival (PFS) in Patients With AJCC Stage IV Metastatic Melanoma Treated With Docetaxel and Vinorelbine as First-line or Post-first Line (Salvage)…
Diabetes Mellitus, Type 2
Primary: Change From Baseline to 26 Weeks in Hemoglobin A1c (HbA1c) — -1.73; -1.36 percentage of HbA1c
Virus Diseases
Primary: Number of Subjects With Solicited Local Symptoms, Overall — 127; 60; 4; 0 Participants
Delirium
Primary: Delirium — 98.0; 56.2; 56.2; 54.8 percent
Spinal Cord Injury
Primary: Body Composition — 31.84; 33.4; 30.75; 32.12 percentage of fat mass
Albinism
Primary: Improved Vision — 0.67; 0.55; 0.53 logMAR
NAFLD
Primary: Change in Hepatic Fat — -10.046; 3.083; -4.013 percentage — p=0.0572
Advanced Adult Hepatocellular Carcinoma · Recurrent Hepatocellular Carcinoma · Stage III Hepatocellular Carcinoma AJCC v7
Primary: Overall Survival — 8.9; 10.5 month — p=0.24
Asthma
Primary: Annualized Rate of On-treatment Exacerbations Per Year — 0.93 Exacerbations per year
Central Post Stroke Pain
Primary: Reduction in Spontaneous Pain Intensity After a Peripheral Nerve Block. — 6.5; 0.0 units on a scale
Delirium
Primary: Number of Patients With Incidence of Delirium Across All Patients at Baseline and Over Post-operative Days 1-3 — 85; 43 Participants — p=0.912
Sarcoma, Soft Tissue
Primary: Progression-Free Survival — 2.64; 1.38 months
Age-Related Macular Degeneration · Macular Degeneration
Primary: Mean Change in Best-corrected Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score — 7.2 letters